关注
Nipun Atreja
Nipun Atreja
未知所在单位机构
在 bms.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Healthcare utilization and costs associated with treatment for opioid dependence
A Shah, M Duncan, N Atreja, KS Tai, M Gore
Journal of medical economics 21 (4), 406-415, 2018
152018
Disease burden following non-cardioembolic minor ischemic stroke or high-risk TIA: a GWTG-Stroke study
BG Kaufman, S Shah, AS Hellkamp, BL Lytle, GC Fonarow, LH Schwamm, ...
Journal of Stroke and Cerebrovascular Diseases 29 (12), 105399, 2020
132020
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases
GYH Lip, A Keshishian, A Kang, X Luo, N Atreja, Y Zhang, P Schuler, ...
Journal of Thrombosis and Thrombolysis 54 (1), 33-46, 2022
92022
New heart failure after myocardial infarction (from the National Cardiovascular Data Registries [NCDR] linked with all-payer claims)
KF Faridi, N Bhalla, N Atreja, J Venditto, ND Khan, T Wilson, E Fonseca, ...
The American Journal of Cardiology 151, 70-77, 2021
82021
Copayment reduction voucher utilization and associations with medication persistence and clinical outcomes: findings from the ARTEMIS trial
AC Fanaroff, ED Peterson, LA Kaltenbach, KJ Anstrom, GC Fonarow, ...
Circulation: Cardiovascular Quality and Outcomes 13 (5), e006182, 2020
82020
Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and multimorbidity
AD Dhamane, M Ferri, A Keshishian, C Russ, N Atreja, C Gutierrez, ...
Advances in Therapy 40 (3), 887-902, 2023
62023
Patients' beliefs regarding counseling provided by community pharmacists: an application of the theory of planned behavior
ML Fleming, EA Ferries, MD Hatfield, N Atreja, A Yucel, PP Rane, ...
Journal of Pharmaceutical Health Services Research 6 (1), 77-79, 2015
52015
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study
S Deitelzweig, A Keshishian, A Kang, A Jenkins, N Atreja, P Schuler, ...
European Journal of Internal Medicine 108, 37-42, 2023
32023
Payer formulary exclusions of apixaban: how patients respond and potential implications
S Deitelzweig, E Terasawa, A Kang, N Atreja, DM Hines, A Noman, X Luo
Current Medical Research and Opinion 38 (11), 1885-1890, 2022
32022
Hospitalization for myocardial infarction with ticagrelor or clopidogrel in patients with acute coronary syndrome: an on-treatment comparative effectiveness analysis
T Olufade, N Atreja, N Bhalla, J Venditto, D Bhandary, K Chafekar, ...
Cardiology and Therapy 10, 515-529, 2021
22021
Translating Clinical Evidence Into Value-Based Payment Models: Pooled Analyses of Innovative Real-World Outcomes Agreements for Ticagrelor in the United States
D Bhandary, N Atreja, DA Belletti, N Bhalla, ND Khan, DS Cobden
American Journal of Managed Care 26 (13), S275-S286, 2020
22020
A real-world evaluation of primary medication nonadherence in patients with nonvalvular atrial fibrillation prescribed oral anticoagulants in the United States
I Hernandez, V Divino, L Xie, DW Hood, M DeKoven, W Kariuki, G Bell, ...
American Journal of Cardiovascular Drugs 23 (5), 559-572, 2023
12023
Payer formulary tier increases of apixaban: how patients respond and potential implications
S Deitelzweig, E Terasawa, N Atreja, A Kang, DM Hines, AD Dhamane, ...
Current Medical Research and Opinion 39 (8), 1093-1101, 2023
12023
PCN101 INPATIENT RESOURCE UTILIZATION IN BRONCHIAL AND LUNG CANCER: ANALYSIS OF 2007 HEALTH CARE UTILIZATION AND PROJECT (HCUP) DATA
B Patel, KM Kamal, N Atreja
Value in Health 3 (13), A43, 2010
12010
Contemporary Predictors of Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention: A Nationally Representative US Sample
BD Horne, N Atreja, J Venditto, T Wilson, JB Muhlestein, JR St. Clair, ...
Journal of Clinical Medicine 13 (10), 2844, 2024
2024
Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims
GYH Lip, V Noxon, A Kang, X Luo, N Atreja, S Han, D Cheng, J Jiang, ...
Journal of Thrombosis and Thrombolysis, 1-11, 2024
2024
EVALUATION OF EFFECTIVENESS AND SAFETY OUTCOMES AMONG MEDICARE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION WHO SWITCHED FROM WARFARIN TO DIRECT ORAL ANTICOAGULANTS
N Atreja, V Noxon, A Kang, D Hines, J Jiang, M Hagan, D Cheng, ...
Journal of the American College of Cardiology 83 (13_Supplement), 1242-1242, 2024
2024
Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation
S Deitelzweig, A Kang, J Jiang, C Gao, X Luo, N Atreja, S Han, D Cheng, ...
Journal of clinical medicine 13 (4), 1073, 2024
2024
The Association between Direct Oral Anticoagulants Prescribing Behavior and Non-Valvular Atrial Fibrillation Outcomes: An Instrumental Variable Analysis of Real-World Data
N Atreja, SG Severtson, J Jiang, C Gao, DM Hines, D Cheng, M Hagan, ...
Journal of Clinical Medicine 12 (22), 7190, 2023
2023
Geographic and Racial Variation in Oral Anticoagulant Treatment Among Commercially Insured Patients With Non-Valvular Atrial Fibrillation in the United States
BD Atwater, R Singh, S Parmar, A Ogbonnaya, A Kang, C Russ, D Cheng, ...
Circulation 148 (Suppl_1), A14004-A14004, 2023
2023
系统目前无法执行此操作,请稍后再试。
文章 1–20